ALS Investment Fund: Financing and supporting biotech solutions for ALS.
5
Operating
2016
Amsterdam, North Holland, NL
ALS Investment Fund focuses on biotech companies developing drugs for neurodegenerative diseases, with a particular emphasis on ALS (Amyotrophic Lateral Sclerosis). The fund invests in early to mid-stage companies, typically participating in Series A and B rounds, with occasional involvement in Series C funding.
Notable portfolio companies include Amylyx Pharmaceuticals, Verge Genomics, and QurAlis. The fund's investment philosophy centers on addressing the challenges of progressive neurological disorders, supporting innovative approaches to tackle diseases that affect memory, muscle control, and other bodily functions. ALS Investment Fund aims to accelerate the development of potential treatments for ALS and related conditions.
Portfolio Snapshot
Recorded participation and recipient operating status, not current holdings or realized exits
Recorded Recipients8
Repeat Participations1
Operating Recipients7
Top Investment Stages
Series A5 (55.6%)
Series B3 (33.3%)
Series C1 (11.1%)
Stage Mix
Series A 56%Series B 33%Series C 11%
Concentration shown as share of disclosed investments by stage.
